Retrospective 459 patients in Iran 93% using HCQ, showing HCQ mortality RR 0.45,
p = 0.028. HCQ was the only antiviral that showed a significant difference. Small number of control patients and subject to confounding by indication. Average admission delay 5.72 days.
Alamdari et al., 9/9/2020, retrospective, Iran, West Asia, peer-reviewed, 14 authors.
risk of death, 55.0% lower, RR 0.45, p = 0.03, treatment 427, control 32.
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of
many trials.